Targeted drugs have been developed in lung adenocarcinoma (LADC) for patients with driven gene positive patients such as epithelial growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) or ROS proto-oncogene 1(ROS1) rearrangements to inhibit tumor progression. This evidence concerns the gene ALK and neoplasm.